Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24066782 | 0.94 | CTSL (0.60) | CTSLFKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL18620867 | 0.91 | ALDH1A1 (0.61) | FKBP1AALDH1A1CYP3A4TSHRPREP | |
| SCHEMBL22209491 | 0.91 | ALDH1A1 (0.61) | FKBP1AALDH1A1CYP3A4TSHRPREP | |
| SCHEMBL18620608 | 0.89 | FKBP1A (0.61) | CTSLFKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL22209524 | 0.89 | FKBP1A (0.61) | CTSLFKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL3469545 | 0.88 | PREP (0.65) | CTSLFKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL10416187 | 0.88 | PREP (0.65) | CTSLFKBP1AALDH1A1CYP3A4TSHR | |
| SCHEMBL7424842 | 0.88 | FKBP1A (0.58) | FKBP1AALDH1A1CYP3A4TSHRPREP | |
| SCHEMBL6435226 | 0.88 | FKBP1A (0.58) | FKBP1AALDH1A1CYP3A4TSHRPREP | |
| SCHEMBL7426375 | 0.88 | FKBP1A (0.62) | FKBP1AALDH1A1CYP3A4TSHRPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | BIRC5, BIRC2, BIRC3 | CTSL 2390/4885FKBP1A 1300/4885ALDH1A1 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.